SecSonar.com

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Rigel Pharmaceuticals, Inc. (RIGL) is a Biotechnology company based in US with a market capitalization of $562.1M. Revenue grew 64.2% year-over-year and the company generated $75.7M in free cash flow. This page tracks RIGL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 162 employees · IPO Nov 29, 2000

Valuation

Valuation & price

$29.01 · as of May 17, 2026 · -43.1% vs 52w high

1.5

P/E ratio

Latest-FY diluted EPS

1.44

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$50.49$34.66$18.84Jul 25Dec 25Jul 26Jul 7, 25$18.84Jul 9, 25$19.04Jul 11, 25$18.88Jul 15, 25$18.90Jul 17, 25$18.91Jul 21, 25$19.59Jul 23, 25$21.07Jul 25, 25$20.17Jul 29, 25$19.90Jul 31, 25$21.06Aug 4, 25$22.67Aug 6, 25$29.81Aug 11, 25$33.46Aug 13, 25$36.58Aug 15, 25$39.51Aug 19, 25$38.94Aug 21, 25$41.99Aug 25, 25$40.74Aug 27, 25$39.73Aug 29, 25$38.85Sep 3, 25$39.61Sep 5, 25$41.34Sep 9, 25$35.93Sep 11, 25$37.82Sep 16, 25$34.98Sep 18, 25$35.11Sep 22, 25$34.45Sep 24, 25$30.28Sep 26, 25$28.63Sep 30, 25$28.33Oct 2, 25$28.12Oct 6, 25$28.90Oct 8, 25$28.76Oct 10, 25$28.18Oct 14, 25$27.38Oct 16, 25$28.11Oct 21, 25$30.27Oct 23, 25$29.39Oct 27, 25$29.58Oct 29, 25$29.40Oct 31, 25$31.58Nov 4, 25$28.38Nov 6, 25$36.12Nov 10, 25$34.55Nov 12, 25$39.94Nov 14, 25$41.94Nov 18, 25$46.22Nov 20, 25$43.84Nov 25, 25$49.56Nov 28, 25$50.49Dec 2, 25$44.41Dec 4, 25$47.38Dec 8, 25$43.40Dec 10, 25$41.22Dec 12, 25$40.78Dec 16, 25$42.02Dec 18, 25$41.77Dec 22, 25$44.16Dec 24, 25$44.64Dec 29, 25$43.08Jan 2, 26$41.83Jan 6, 26$43.28Jan 8, 26$44.50Jan 12, 26$39.96Jan 14, 26$39.12Jan 16, 26$37.48Jan 21, 26$37.64Jan 23, 26$36.96Jan 27, 26$37.25Jan 29, 26$35.16Feb 2, 26$36.01Feb 4, 26$34.95Feb 9, 26$34.41Feb 11, 26$34.94Feb 13, 26$34.32Feb 18, 26$35.72Feb 20, 26$35.46Feb 24, 26$34.51Feb 26, 26$35.71Mar 2, 26$34.62Mar 4, 26$29.63Mar 6, 26$28.87Mar 10, 26$28.44Mar 12, 26$26.60Mar 17, 26$26.38Mar 19, 26$26.10Mar 23, 26$26.50Mar 25, 26$26.29Mar 27, 26$25.81Mar 31, 26$27.04Apr 2, 26$27.53Apr 7, 26$28.73Apr 9, 26$30.51Apr 13, 26$29.97Apr 15, 26$32.06Apr 17, 26$32.43Apr 22, 26$30.47Apr 24, 26$30.29Apr 28, 26$30.56Apr 30, 26$28.90May 4, 26$29.54May 6, 26$26.67May 8, 26$26.04May 12, 26$29.37May 14, 26$31.92May 18, 26$28.61May 20, 26$28.82May 22, 26$29.01May 28, 26$30.05Jun 1, 26$29.86Jun 3, 26$30.30Jun 5, 26$29.93Jun 9, 26$30.72Jun 11, 26$32.08Jun 15, 26$33.42Jun 17, 26$33.37Jun 22, 26$35.73Jun 24, 26$36.55Jun 26, 26$38.69Jul 2, 26$38.72
$18.4252-week range$50.96
Loading valuation history…

Fundamentals

Key fundamentals

$562.1M

Market cap

64.2%

Revenue growth (YoY)

93.3%

Gross margin

$75.7M

Free cash flow (USD)

-$101.7M

Net debt

Net cash position

2.3%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$20.4MFY 2017$4.5MFY 2018$44.5MFY 2019$59.3MFY 2020$108.6MFY 2021$149.2MFY 2022$120.2MFY 2023$116.9MFY 2024$179.3MFY 2025$294.3M
$20.4M$294.3M

Free cash flow by year

2016 → 2025

FY 2016$-76.7MFY 2017$-77.7MFY 2018$-59.9MFY 2019$-43.0MFY 2020$-53.4MFY 2021$5.3MFY 2022$-74.2MFY 2023$-20.7MFY 2024$31.1MFY 2025$75.7M
-$76.7M$75.7M

Gross margin by year

2021 → 2025

FY 202199.3%FY 202298.5%FY 202393.9%FY 202489.6%FY 202593.3%
99.3%93.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventExecutive AppointmentJul 1, 2026Filing
  • Insider sellInsider Sell $88K · 10b5-1 PlanAli-Jackson Kamil · Director · $87.5KJun 24, 2026Filing
  • 8-K eventAcquisition CompletedJun 17, 2026Filing
  • Insider sellInsider Sell $73K · 10b5-1 PlanAli-Jackson Kamil · Director · $72.9KMay 28, 2026Filing
  • 8-K eventStockholder Meeting ResultsMay 20, 2026Filing
  • 8-K eventLicense Agreement SignedMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • 8-K eventTermination of AgreementApr 21, 2026Filing

Questions

Frequently asked questions

What is Rigel Pharmaceuticals, Inc.'s market cap?

Rigel Pharmaceuticals, Inc. (RIGL) has a market capitalization of $562.1M.

What is RIGL's P/E ratio?

RIGL trades at a price-to-earnings ratio of 1.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is RIGL's price-to-book (P/B) ratio?

RIGL trades at 1.44 times book value per share.

Are insiders buying RIGL stock?

SEC Form 4 filings show no open-market insider buys at Rigel Pharmaceuticals, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

VALN

Valneva SE

$563.3M

MDXG

MiMedx Group, Inc.

$553.3M

ARVN

Arvinas, Inc.

$572M

GYRE

Gyre Therapeutics, Inc.

$572.7M

ACRS

Aclaris Therapeutics, Inc.

$546.3M

CTMX

CytomX Therapeutics, Inc.

$582.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.